Welcome to our dedicated page for Akari Therapeutics news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics stock.
Akari Therapeutics plc develops oncology antibody-drug conjugates built around RNA splicing modulator payloads. News about AKTX centers on its ADC platform, the PH1 payload technology, and lead program AKTX-101, a TROP2-targeted ADC studied in solid tumor models including bladder, lung and breast cancer. Updates also cover intellectual-property protection for the company’s payload chemistry and therapeutic applications.
Recurring company developments include preclinical data releases, oncology conference abstracts, strategic development collaborations, capital-structure disclosures, governance matters, and American Depositary Share program updates. As an ADR issuer, Akari’s news may also address ordinary-share and ADS mechanics tied to Nasdaq listing requirements and shareholder approvals.
Akari Therapeutics (Nasdaq: AKTX) announced a successful initial closing of a private placement financing round, raising approximately $7.6 million in gross proceeds. The financing garnered strong support from both new and existing investors, highlighted by Akari's Chairman, Dr. Ray Prudo, and Interim President and CEO, Dr. Samir R. Patel. The funds will support Akari's strategic initiatives, including their upcoming merger with Peak Bio, expected to close in Q3 2024. The financing involved the sale of 4,029,754 unregistered ADSs and Series C Warrants to purchase an equal number of ADSs at $1.885 per unit. The warrants have a three-year term and cashless exercise provisions, with different exercise prices for company executives and other investors.
Akari Therapeutics (Nasdaq: AKTX), a late-stage biotechnology firm, reported its first-quarter 2024 financial results, announcing a net loss of $5.6 million and highlighting recent activities. The company entered into a definitive merger agreement with Peak Bio, anticipated to close in Q3 2024. The combined entity will prioritize Peak's ADC cancer therapeutic platform and Akari's PAS-nomacopan for Geographic Atrophy. A restructuring plan has commenced, reducing the workforce by 67% to cut operating costs. Akari issued $1 million in unsecured convertible notes to secure operational capital. Research and development expenses rose to $2.3 million, while general and administrative costs increased to $3.7 million, compared to the same period in 2023.
Summary: Akari Therapeutics, Plc announced the appointment of Samir R. Patel, M.D. as interim CEO, replacing Rachelle Jacques. Dr. Patel aims to complete the merger with Peak Bio, prioritize the company's portfolio, and advance its lead compound, nomacopan. The leadership changes are expected to bring cost savings through reduced clinical trial and infrastructure expenses.
Akari Therapeutics and Peak Bio have announced a joint portfolio prioritization plan following their merger, focusing on Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy. The companies aim to secure business development opportunities and funding while advancing these key programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.